Skip to content

AbbVie ABBV Share Buybacks

Share Buybacks at other companies

Eli Lilly logo
Eli LillyLLY
$2.36B+96.3%
Johnson & Johnson logo
Johnson & JohnsonJNJ
$4.03B+89.4%
Cardinal Health logo
Cardinal HealthCAH
$250M-33.3%
Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
$336.9M-20.9%
McKesson logo
McKessonMCK
$2.67B+790%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
$0-100%

Other financials

Income statement

See full
Revenue$15.0B+12.4%
Gross profit$10.8B+15.4%
Operating income$4.0B+6.9%
Net income$695.0M-46.0%
EPS (diluted)$0.39-45.8%

Balance sheet

See full
Cash & equivalents$9.4B+81.5%
Total debt$62.4B+1.8%
Total equity-$6.7B-569%
Total assets$136.46B+0.2%

Cash flow

See full
Operating cash flow$3.8B+134%
CapEx$265.0M+12.8%
Free cash flow$3.6B+155%

Valuation

See full
Market cap$447.62B+36.6%
P/E123.1×+36.0×
P/S7.1×+1.5×

Profitability

See full
Gross margin70.7%0.0pp
Operating margin24.4%
Net margin5.8%-1.5pp
FCF margin31.8%+5.0pp

Returns & leverage

See full
Return on equity89%+32.7pp
Debt / equity46.6×+38.6×
Current ratio0.8×0.0×

Where this comes from

Reported directly by AbbVie in its filing.

Tagged under the XBRL concept us-gaap:PaymentsForRepurchaseOfCommonStock.

The official record: AbbVie’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about AbbVie's share buybacks.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is AbbVie's share buybacks?
AbbVie (ABBV) reported share buybacks of $1.49B in Q1 2026.
How has AbbVie's share buybacks changed year-over-year?
AbbVie's share buybacks increased by 54.9% year-over-year, from $961M to $1.49B.
What is the long-term trend for AbbVie's share buybacks?
Over 4 years (2021 to 2025), AbbVie's share buybacks has grown at a 1.2% compound annual growth rate (CAGR), from $934M to $980M.
What does share buybacks mean?
Cash used to buy back the company's own shares on the open market or through structured programs, reducing shares outstanding.